Hildegard Christ

Hildegard Christ

Auto-generated profile, based on publicly available information

Hildegard Christ

Institute of Medical Statistics and Computational Biology (IMSB), University Hospital of Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
NMNassir F. Marrouche
Nassir F. Marrouche
JBJohannes Brachmann
Johannes Brachmann
DADietrich Andresen
Dietrich Andresen
JSJürgen Siebels
Jürgen Siebels
LBLucas Boersma
Lucas Boersma
DBDietmar Bänsch
Dietmar Bänsch
Mortality and morbidity are higher among patients with atrial fibrillation and heart failure than among those with heart failure alone. Catheter ablation for atrial fibrillation has been proposed as a means of improving outcomes among patients with heart failure who are otherwise receiving appropriate treatment.

2 December 2003 in International Journal of Obesity
Verified
Journal Article
Closed access
CGC Graf
C Graf
BKB Koch
B Koch
EKE Kretschmann-Kandel
E Kretschmann-Kandel
GFG Falkowski
G Falkowski
HCH Christ
H Christ
SDS Dordel
S Dordel

1 September 2016 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
EREberhard Roeseler
Eberhard Roeseler
UJUlrich Julius
Ulrich Julius
FHFranz Heigl
Franz Heigl
RSRalf Spitthoever
Ralf Spitthoever
DHDennis Heutling
Dennis Heutling
CFCordula Fassbender
Cordula Fassbender
Objective—: Lipoprotein(a)-hyperlipoproteinemia (Lp(a)-HLP) along with progressive cardiovascular disease has been approved as indication for regular lipoprotein apheresis (LA) in Germany since 2008. We aimed to study the long-term preventive effect of LA and to assess hypothetical clinical correlations of apolipoprotein(a) (apo(a)) by analyzing genotypes and phenotypes. Approach and Results—: This prospective observational multicenter study included 170 patients with Lp(a)-HLP and progressive cardiovascular disease (48.9 years median age at diagnosis) despite other cardiovascular risk factors, including low-density lipoprotein cholesterol had maximally been treated (mean baseline low-density lipoprotein cholesterol: measured, 2.56 mmol/L [98.9 mg/dL] and corrected, 1.72 mmol/L [66.3 mg/dL]). Patients were prospectively investigated during a 5-year period about annual incidence rates of cardiovascular events. In addition, apo(a) isoforms and polymorphisms at the apo(a) gene ( LPA ) were characterized. One hundred fifty-four patients (90.6%) completed 5 years of follow-up. Mean Lp(a) concentration before commencing regular LA was 108.1 mg/dL. This was reduced by a single LA treatment by 68.1% on average. Significant decline of the mean annual cardiovascular event rate was observed from 0.58±0.53 2 years before regular LA to 0.11±0.15 thereafter ( P <0.0001); 95.3% of patients expressed at least 1 small apo(a) isoform. Small apo(a) isoform (35.2%) carrying phenotypes were not tagged by single-nucleotide polymorphisms rs10455872 or rs3798220. Conclusions—: Results of 5 years of prospective follow-up confirm that LA has a lasting effect on prevention of cardiovascular events in patients with Lp(a)-HLP. Patients clinically selected by progressive cardiovascular disease were characterized by a highly frequent expression of small apo(a) isoforms. Only Lp(a) concentration seemed to comprehensively reflect Lp(a)-associated cardiovascular risk, however.

7 July 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
LVLinus Alexander Völker
Linus Alexander Völker
JKJessica Kaufeld
Jessica Kaufeld
WMWolfgang Miesbach
Wolfgang Miesbach
SBSebastian Brähler
Sebastian Brähler
MRMartin Reinhardt
Martin Reinhardt
JMJan Menne
Jan Menne
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with initial disease presentation and in 4 additional patients with laboratory signs of an exacerbation or relapse after the initial therapy, PEX-free treatment regimens could be established with overall favorable outcome. Caplacizumab is efficacious in the treatment of aTTP independent of timing and ancillary treatment modalities. Based on this real-world experience and published literature, we propose to administer caplacizumab immediately to all patients with an acute episode of aTTP. Treatment decisions regarding the use of PEX should be based on the severity of the clinical presentation and known risk factors. PEX might be dispensable in some patients.

1 February 2006 in The American Journal of Pathology
Verified
Journal Article
Closed access
DRDetlev Roth
Detlev Roth
MPMichael Piekarek
Michael Piekarek
MPMats Paulsson
Mats Paulsson
HCHildegard Christ
Hildegard Christ
WBWilhelm Bloch
Wilhelm Bloch
SESabine A. Eming
Sabine A. Eming

29 October 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
FBFelix Berlth
Felix Berlth
MBMarc Bludau
Marc Bludau
PPPatrick Sven Plum
Patrick Sven Plum
THTill Herbold
Till Herbold
HCHildegard Christ
Hildegard Christ
SCSeung-Hun Chon
Seung-Hun Chon